LRT Capital Management LLC Buys New Position in Eli Lilly and Company (NYSE:LLY)

LRT Capital Management LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 915 shares of the company’s stock, valued at approximately $533,000.

Other hedge funds also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the third quarter valued at about $27,000. Retirement Group LLC increased its holdings in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $33,000. Finally, Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at about $35,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Finally, Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Trading Down 2.6 %

Shares of NYSE LLY traded down $19.64 during trading on Friday, reaching $726.31. The stock had a trading volume of 3,505,526 shares, compared to its average volume of 2,202,924. Eli Lilly and Company has a fifty-two week low of $369.76 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business’s 50-day moving average price is $763.96 and its 200-day moving average price is $660.53. The company has a market cap of $690.11 billion, a P/E ratio of 125.23, a PEG ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the firm posted $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.